Cargando…

Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a disease that progress over time and is defined as an increase in pulmonary arterial pressure and pulmonary vascular resistance that frequently leads to right-ventricular (RV) failure and death. Epigenetic modifications comprising DNA methylation, histone re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Linh, Hossen, Nazir, Nguyen, Trieu, Vo, Au, Ahsan, Fakhrul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773438/
https://www.ncbi.nlm.nih.gov/pubmed/35052850
http://dx.doi.org/10.3390/biomedicines10010170
_version_ 1784636087157653504
author Ho, Linh
Hossen, Nazir
Nguyen, Trieu
Vo, Au
Ahsan, Fakhrul
author_facet Ho, Linh
Hossen, Nazir
Nguyen, Trieu
Vo, Au
Ahsan, Fakhrul
author_sort Ho, Linh
collection PubMed
description Pulmonary arterial hypertension (PAH) is a disease that progress over time and is defined as an increase in pulmonary arterial pressure and pulmonary vascular resistance that frequently leads to right-ventricular (RV) failure and death. Epigenetic modifications comprising DNA methylation, histone remodeling, and noncoding RNAs (ncRNAs) have been established to govern chromatin structure and transcriptional responses in various cell types during disease development. However, dysregulation of these epigenetic mechanisms has not yet been explored in detail in the pathology of pulmonary arterial hypertension and its progression with vascular remodeling and right-heart failure (RHF). Targeting epigenetic regulators including histone methylation, acetylation, or miRNAs offers many possible candidates for drug discovery and will no doubt be a tempting area to explore for PAH therapies. This review focuses on studies in epigenetic mechanisms including the writers, the readers, and the erasers of epigenetic marks and targeting epigenetic regulators or modifiers for treatment of PAH and its complications described as RHF. Data analyses from experimental cell models and animal induced PAH models have demonstrated that significant changes in the expression levels of multiple epigenetics modifiers such as HDMs, HDACs, sirtuins (Sirt1 and Sirt3), and BRD4 correlate strongly with proliferation, apoptosis, inflammation, and fibrosis linked to the pathological vascular remodeling during PAH development. The reversible characteristics of protein methylation and acetylation can be applied for exploring small-molecule modulators such as valproic acid (HDAC inhibitor) or resveratrol (Sirt1 activator) in different preclinical models for treatment of diseases including PAH and RHF. This review also presents to the readers the application of microfluidic devices to study sex differences in PAH pathophysiology, as well as for epigenetic analysis.
format Online
Article
Text
id pubmed-8773438
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87734382022-01-21 Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension Ho, Linh Hossen, Nazir Nguyen, Trieu Vo, Au Ahsan, Fakhrul Biomedicines Review Pulmonary arterial hypertension (PAH) is a disease that progress over time and is defined as an increase in pulmonary arterial pressure and pulmonary vascular resistance that frequently leads to right-ventricular (RV) failure and death. Epigenetic modifications comprising DNA methylation, histone remodeling, and noncoding RNAs (ncRNAs) have been established to govern chromatin structure and transcriptional responses in various cell types during disease development. However, dysregulation of these epigenetic mechanisms has not yet been explored in detail in the pathology of pulmonary arterial hypertension and its progression with vascular remodeling and right-heart failure (RHF). Targeting epigenetic regulators including histone methylation, acetylation, or miRNAs offers many possible candidates for drug discovery and will no doubt be a tempting area to explore for PAH therapies. This review focuses on studies in epigenetic mechanisms including the writers, the readers, and the erasers of epigenetic marks and targeting epigenetic regulators or modifiers for treatment of PAH and its complications described as RHF. Data analyses from experimental cell models and animal induced PAH models have demonstrated that significant changes in the expression levels of multiple epigenetics modifiers such as HDMs, HDACs, sirtuins (Sirt1 and Sirt3), and BRD4 correlate strongly with proliferation, apoptosis, inflammation, and fibrosis linked to the pathological vascular remodeling during PAH development. The reversible characteristics of protein methylation and acetylation can be applied for exploring small-molecule modulators such as valproic acid (HDAC inhibitor) or resveratrol (Sirt1 activator) in different preclinical models for treatment of diseases including PAH and RHF. This review also presents to the readers the application of microfluidic devices to study sex differences in PAH pathophysiology, as well as for epigenetic analysis. MDPI 2022-01-13 /pmc/articles/PMC8773438/ /pubmed/35052850 http://dx.doi.org/10.3390/biomedicines10010170 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ho, Linh
Hossen, Nazir
Nguyen, Trieu
Vo, Au
Ahsan, Fakhrul
Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
title Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
title_full Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
title_fullStr Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
title_full_unstemmed Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
title_short Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
title_sort epigenetic mechanisms as emerging therapeutic targets and microfluidic chips application in pulmonary arterial hypertension
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773438/
https://www.ncbi.nlm.nih.gov/pubmed/35052850
http://dx.doi.org/10.3390/biomedicines10010170
work_keys_str_mv AT holinh epigeneticmechanismsasemergingtherapeutictargetsandmicrofluidicchipsapplicationinpulmonaryarterialhypertension
AT hossennazir epigeneticmechanismsasemergingtherapeutictargetsandmicrofluidicchipsapplicationinpulmonaryarterialhypertension
AT nguyentrieu epigeneticmechanismsasemergingtherapeutictargetsandmicrofluidicchipsapplicationinpulmonaryarterialhypertension
AT voau epigeneticmechanismsasemergingtherapeutictargetsandmicrofluidicchipsapplicationinpulmonaryarterialhypertension
AT ahsanfakhrul epigeneticmechanismsasemergingtherapeutictargetsandmicrofluidicchipsapplicationinpulmonaryarterialhypertension